July 22nd 2024
Survival results from the phase 3 CheckMate –9DW trial support the application for the combination therapy in treating hepatocellular carcinoma.
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Sorafenib Plus SBRT Yields Improved Survival Vs Sorafenib Alone in Locally Advanced HCC
October 25th 2022Stereotactic body radiation therapy is a new standard of care option for patients with locally advanced hepatocellular carcinoma, according to a presentation on the phase 3 NRG/RTOG 1112 trial assessing sorafenib combined with stereotactic body radiation therapy.
FDA Grants Orphan Drug Designation to ET140203 T Cells for Hepatoblastoma
October 19th 2022The FDA has given orphan drug designation to ET140203 ARTEMIS, an investigational therapy for hepatoblastoma, the safety and potential efficacy of which are being evaluated in the phase 1/2 ARYA-1 and ARYA-2 studies.
FDA Grants Priority Review to Tremelimumab for Unresectable HCC
April 26th 2022Tremelimumab’s biologics license application was accepted by the FDA and was given priority review, further supporting the use of a single priming dose of anti-CTLA4 plus durvalumab in unresectable hepatocellular carcinoma.
Addition of Best Supportive Care to Pembrolizumab Significantly Improved Survival for Advanced HCC
January 21st 2022Patients with advanced hepatocellular carcinoma achieved a statically significant and clinically meaningful survival benefit following treatment with pembrolizumab and best supportive care in the second line.
NovoTTF-200T Delivery System Given a Breakthrough Designation by the FDA for Advanced Liver Cancer
September 10th 2021The NovoTTF-200T System was given a breakthrough designation by the FDA as treatment strategy that may work in conjunction with bevacizumab and atezolizumab to treat patients with advanced liver cancer.